Estimate levels of some cytokine in patient infection with *Helicobacter pylori*

Suroor Ali Shalash

Dr. Rajwa Hasen Essa Dr. Mohammed Issa Muhsin

College of Science, Al-Mustansiriya University

ABSTRACT

This study includes a collection of 140 samples of blood which have been collected from patient infected with $H.\ pylori$, these samples were collected from AL – Kindy Teaching Hospital in a period from (November- 2015 to March - 2016) with age ranging from 15-70 years .

The results showed that from 140 blood samples diagnosis infection with H.pylori by rapid test and make confirmatory for the infection by ELISA technique, make ELISA IgG test technique in this test give 60 patients. Measure the serum level cytokine in the patient infected with H.pylori explain that anti-inflammatory IL-6 chronic phase: $(391\pm5.4 \text{ pg/ml})$ and acute phase : $(218.6\pm7.7 \text{ pg/ml})$. In the cytokine pro inflammatory TNF- α chronic phase : $(391.8\pm8.6 \text{ pg/ml})$ and acute phase : $(290\pm11.3 \text{ pg/ml})$ and in the proinflammatory MIF cytokine chronic phase : $(45.05\pm2.5 \text{ pg/ml})$ and acute phase : $(29.08\pm2.1 \text{ pg/ml})$.

INTRODUCTION

Helicobacter pylori previously Campylobacter pylori, is a gram-negative, microaerophilic bacterium found usually in the stomach. It was identified in 1982 by Australian scientists Barry Marshall and Robin Warren (1). Up to 85% of people infected with *H. pylori* never experience symptoms or complications (2). Acute infection may appear as an acute gastritis with abdominal pain (stomach ache) or nausea (3). Where this develops into chronic gastritis, the symptoms, if present, are often those of non-ulcer dyspepsia: stomach pains, nausea, bloating, belching, and sometimes vomiting or black stool (4). Its spiral shape and flagella allow it to corkscrew through the gastric mucus gel, and numerous adhesions enable selective adherence to the epithelium . H.pylori mechanisms for protection against gastric acid; notably, 15% of its protein content comprises preformed cytoplasmic urease. When the external PH is less than 6.5, a specific channel opens in the bacterial cytoplasmic membrane, allowing ingress of urea (5). Oral-to-oral, fecal-to-oral, and gastric-to-oral transmission account for most infections (6). Accordingly,

improvements in hygiene and living conditions are important factors in decreasing the prevalence of infection (7). There have also been association studies with maternal infection and socioeconomic status being an important risk factor for pediatric infection (8, 9) . *H.pylori* bacteria have several virulence factor such as urease ,flagella , and Vaculating cytotoxin A (VacA) (10) . The aimed of this is to study detect the level of the cytokine in the serum of the patient .

MATERIAL AND METHOD

One hundred and forty specimens of blood took from patient infected with of *H.pylori* with age ranging 15-70 years ,diagnosis the specimens of blood by Rapid Anti *H.pylori* Test in this test patient infection with *H.pylori* positive give two pink lines in the test line and control line if *H.pylori* negative in the control line only give pink and also make immunological test as confirmation test by ELISA test IgG (DIAsource) *H.pylori* give sixty from eighty four total patient (11). This research studied the level of the cytokine in the patient infection with *H.pylori*.

Table (1) comparison between levels of TNF- α in serum of the patient infected with H.pylori and control

itii 11.pytort and control				
Patient`s phase	TNF-α (pg/ml)			
_	Mean ±SD			
Chronic	391.8±8.6			
No.	20			
Acute	290±11.3			
No .	40			
Control Healthy	7.25±0.0*			
No.	20			
Positive Control	241			
(P<0.05)				

P: Probability Compared to Control P< 0.05.

Table (2) comparison between levels of IL-6 in the serum patient infected with *H.pylori* and control

Patient`s phase	IL-6(pg/ml) Mean ± SD
Chronic	391±5.4
No.	20
Acute	218.6±7.7
No.	40
Control Healthy	36.25±3.5*
No.	20
positive Control P<0.05) (285

P: Probability Compared to Control P< 0.05.

^{*:} Significant differences between patient and control .

^{*:} Significant differences between patient and control

Table (3) serum level of MIF in acute and chronic phase of dyspeptic ulcer patient

Patient phase	MIF (pg/ml)
_	Mean ±SD
Chronic	45.05±2.5
No.	20
Acute	29.08±2.1
No.	40
Healthy control	17.5±2.1*
No.	20
P<0.05) (

P: Probability Compared to Control P< 0.05.

Table (4) explain serum levels of all cytokine in this study and compared between them

Type of cytokines	Chronic	Acute	Control		
IL-6(pg/ml)	391 ±5.4	218.6±7.7	36.25 ±3.5*		
TNF-α(pg/ml)	391.8±8.6	290±11.3	7.25±0.0*		
MIF (pg/ml)	45.05±2.5	29.08±2.1	17.55±2.1*		
P<0.05) (

P: Probability Compared to Control P< 0.05.

DISCUSSION

Anti inflammatory cytokine TNF- α is released in response to infection and inflammation produced by activated macrophage and lymphocytes which are found over expression TNF $-\alpha$ with the advance lymph nodal metastasis (12). In this study the serum levels of patient group was high compared with control group ,and statistical analysis give significant differences between patients and control group at P < 0.05

. Fan *et al* ,1993 showed that anti inflammatory cytokine (TNF- α) has higher levels of production by antral mucosa cells in *H.pylori* infection may reflect the mucosal infiltration by macrophages and T lymphocytes (13).

Proinflammatory IL-6 is being regarded as a main cytokine in progression pathway of chronic inflammatory process . It is multi functional protein produced by monocytes , endothelial cells ,the cell fibroblast , and mast cells (12) .Level of the pro inflammatory cytokine IL-6 is high in the patient infected with H.pylori bacteria the plasma cells differentiation in the acute phase to stimulate antibody secretion IL-6 . In the chronic phase the concentration of IL-6 is also elevated in compared with control depression. In this study results show a high level of IL-6 in patient group as compared with control group , and statistical analysis give significant differences between patients and control group at p < 0.05.

^{*:} Significant differences between patients and control.

^{*:} Significant differences between patients and control

MIF is a proinflammatory cytokine with several actions(14). This cytokine an initial inflammatory mediator stimulates expression of other cytokines such as TNF- α and IL-1(15). Infection of *H.pylori* is also associated with increased expression of proinflammatory MIF in macrophages and T cells and in the lamina propria. In this study the results show high level of proinflammatory cytokine MIF in patient group as compared with control group , and statistical analysis give significant differences between patient and control groups at p< 0.05 .

In the begging the interaction between *H.pylori* and innate immune response for the host is mediated through surface receptors expressed on gastric epithelial cells and antigen –presenting cells (APCs –DCs and macrophages) (16).

Gastric of human activation DCs via H.pylori directs naive CD4+ T cells to Th1 differentiation through IL-12 production and can these cells to secrete cytokines like TNF- α ,IL-1,IL-6 and IFN- γ via activation of the Stt4 (signal transducer and activation of transcription factor 4) and transcription factors T –bet (T box expressed in T cell) (17). The conclusion of this study is that :Rapid test of H.pylori is an important in primary diagnosis infection of dyspeptic ulcer H.pylori in addition to that of ELISA IgG is more sensitive and specific for confirmation H.pylori infection as a serological test. Concentrations of serum level Tumor necrotic factor alpha (TNF – α) , Interleukin -6 (IL-6) and Migration inhibition factor (MIF) increased significantly compared to control group during H.pylori infection specially at chronic phase of disease so these serum factors can be use as immunological markers for detection infection of H.pylori if it is acute or chronic .

REFERENCES

- 1-Blaser, M.J. (2006). Who are we? Indigenous microbes and the ecology of human diseases (PDF). EMBO Reports 7 (10): 956–60.
- 2-Bytzer, P.; Dahlerup, J.F.; Eriksen, J.R.; Jar, D.E.; Rosenstock, S.; Wildt,S. (2011).Diagnosis and treatment of *Helicobacter pylori* infection. Dan Med Bull 58 (4): C4271. PMID 21466771. Retrieved 7 August 2013.
- 3- Butcher, Graham, P. (2003). Gastroenterology: An Illustrated Colour Text. Elsevier Health Sciences. p. 25.
- 4- Ryan, Kenneth .(2010). Sherris Medical Microbiology. McGraw-Hill. pp. 573, 576.
- 5 Atherton ,J.C.; and Blaser ,M.J.(2009). Coadaptation of *Helicobacter pylori* and human :ancient history , modern implication, J Clin Invest. 119 (9): 2475 2487.

- 6- Everhart, J. E. (2000). Recent developments in the epidemiology of *Helicobacter pylori*. Gastroenterol. Clin. North Am. 29:559-578.
- 7- Vale, F.F.; Vítor, J.M.B.(2010). Transmission pathway of *Helicobacter pylori*: does food play a role in rural and urban areas? Int J Food Microbiol.138: 1–12.
- 8 –Bassily, S.;Frenck,R.W.; Mohareb, E.W.; Wierzba ,T. (1999) Seroprevalence of *Helicobacter pylori* among Egyptian newborns and their mothers: a preliminary report. Am J Trop Med Hyg. 61: 37–40.
- 9- Opekun, A.R.; Gilger, M.A.; Denyes, S.M.; Nirken, M.H.; Philip, S.P.; Osato, M.S.; Malaty, H.M.; Hicks, J.; Graham, D.Y. (2000). *Helicobacter pylori* infection in children of Texas. J Pediatr Gastroenterol Nutr. 31: 405–10.
- 10- Delahay, R. M. and ;Rugge, M. (2012).Pathogenesis of *Helicobacter pylori* Infection. Helicobacter. 17 (1): 9-159.
- 11- Vaira ,D.; Ainleny ,C.; Williams ,S.; Cairms ,S.; Salmon ,P.; Russell, C.; and Cotton ,P. (1989). Endoscopic sphincterotomy in 1000 consecutive patients . *The Lancet* .334(8660) , 431-434.
- 12- Chaturmohta, A.; Dixit, R.; Narayan, G.; Gupta, P., and Prasad, S.B. (2015). Do Expression Profiles of Cytokines VEGF, TNF- α, IL-1β, IL-6 and IL-8 Correlate with Gallbladder Cancer? J Cancer Sci Clin Oncol.202(2).
- 13- Fan, X.J.; Chua, A.; and O'Connell, M.A.(1993). Interferon-gamma and tumour necrosis factor production in patients with *Helicobacter pylori* infection. Ir J Med Sci. 162:408–411.
- 14 Shimizu, T. (2010). The Role of Macrophage Migration Inhibitory Factor (MIF) in Ultraviolet Radiation-Induced Carcinogenesis .9.2(3):1555-64.
- 15 Agnes, E.; Coutinho, and Karen, E. Chapman. (2011). The antiinflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 335(1): 2– 13.
- 16- Watanabe, T.; Asano, N.; Fichtner-Feigl, S.; Gorelick, P.L.; Tsuji, Y.; Matsumoto, Y.; Chiba, T.; Fuss, I.J.; Kitani, A.; and Strober, W.(2010) NOD1 contributes to mouse host defense against *Helicobacter pylori* via induction of type I IFN and activation of the ISGF3 signaling pathway. J Clin Invest.120:1645–1662.
- 17- Bimczok , D.; Clements , R.H.; Waites, K.B.; Novak, L.; Eckhoff, D.E.; Mannon, P.J.; Smith, P.D.; and Smythies, L.E.(2010). Human

primary gastric dendritic cells induce a Th1 response to *H. pylori*. Mucosal Immunol. 3:260–269.

الخلاصه

تم جمع 140 عينة من الدم من مرضى مصابين ببكتيريا H. Pylori هذه العينات تم جمعها من مستشفى الكندي التعليمي في الفترة من (تشرين الثاني 2015 اذار 2016) تتراوح اعمارهم بين 15 -70 عاما.

وأظهرت النتائج 140 عينه دم تم تشخيصها بالاصابة ببكتيريا H. Pylori بواسطة اختبار سريع وتم تأكيد الإصابة بواسطة تقنية ELIAS IgG في هذا الاختبار اعطى 60 شخص مصاب . قياس مستوى المصل الخلوي في المريض المصاب ببكتيريا H. Pylori يوضح ان عوامل ضد الالتهاب 6-11 في المريض ذو الاصابة طويلة الامد: (IL-6 IL-6) و IL-7.7 IL-10 المحلول المصلي الخلوي ما قبل للالتهابي IL-7.7 IL-11 في المحلول المصلي الخلوي ما قبل للالتهابي IL-11 و الاصابة الحادة : (IL-11 IL-12 IL-13 IL-14 و الاصابة الحادة : (IL-14 IL-15 IL-16 IL-16 IL-17 IL-18 IL-19 و الاصابة الحادة : (IL-18 IL-19 و الاصابة الحادة : (IL-19 IL-19 IL-19 و الاصابة الحادة : (IL-19 IL-19 IL-19